POAI Stock: Predictive Oncology Inc. Stock Price, Analysis & Insights
Get live poai stock price $4.26, comprehensive Predictive Oncology Inc. stock analysis, charts, news, and expert forecast. Real-time poai stock data and investment insights.
Loading chart...
Company Overview
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Company Information
- CEO
- Raymond F. Vennare
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 23
Contact Information
- Address
- 2915 Commers Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.35)
Business Model & Strategy
Predictive Oncology Inc. operates in the Medical - Instruments & Supplies industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Raymond F. Vennare, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Instruments & Supplies model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Predictive Oncology Inc. competes in the Medical - Instruments & Supplies within the broader Healthcare. With 3.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Predictive Oncology Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Predictive Oncology Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Predictive Oncology Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Predictive Oncology Inc.
- ⚠Investors should consider how Predictive Oncology Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
3.09M
P/E Ratio
-0.03
Beta
1.35
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 3.09M market capitalization
- Trading Volume: 66.47K shares traded today
- Price Range: 52-week range of $3.88 - $45.90
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Predictive Oncology Inc.
Predictive Oncology Inc. (POAI) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. With a current market capitalization of 3.09M, the company represents a significant player in its market. The stock is currently trading at $4.26 with a negativedaily change of 22.19%.
The company's 23 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.03, beta of 1.35, and 52-week price range from $3.88 to $45.90when evaluating investment opportunities.
Why Invest in Predictive Oncology Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Raymond F. Vennare
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.